Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer

In this podcast episode, listen to lung cancer experts Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for patients with early-stage and advanced NSCLC.
Julie Brahmer, MD, MSc
person default
Jarushka Naidoo, MB BCH BAO, MHS
Released: November 23, 2021

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:

  • Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens
  • Second-line therapeutic options after disease progression on an immunotherapy-based regimen
  • Immunotherapy in patients with advanced NSCLC and brain metastases
  • Distinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsy
  • Future directions in immunotherapy for NSCLC, including the role of the gut microbiome in response

Information on this Educational Activity

Faculty

Julie Brahmer, MD, MSc

Professor of Oncology
Director, 
Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Julie Brahmer, MD, MSc, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Lilly, Merck, Regeneron, and Sanofi; funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics, and Revolution Medicines; and fees for non-CME/CE services from GlaxoSmithKline, Janssen, and Sanofi.
Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS, has disclosed that she has received consulting fees from AstraZeneca, Daiichi Sankyo, Merck, Pfizer, Roche/Genentech, and Takeda and funds for research support from AstraZeneca and Merck.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
Helsinn Healthcare SA
Merck Sharp & Dohme Corp.

Related Content

Clinical Care Options (CCO) commentary: Joel Neal, MD, discusses management of non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations

Joel W. Neal, MD, PhD Released: May 20, 2022

Podcast with Dr. Nelson F. Sanchez on caring for transgender individuals, from the healthcare disparities they face to how HCPs can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: May 13, 2022

On-demand webcast on biomarker-driven care for patients with NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Downloadable slides for oncologists, pharmacists, and nurses: Immunotherapy and chemotherapy for extensive-stage SCLC from Clinical Care Options (CCO)

Released: May 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings